RANKL: A promising circulating marker for bone metastasis response
- 8 August 2016
- journal article
- Published by Spandidos Publications in Oncology Letters
- Vol. 12 (4) , 2970-2975
Abstract
Bone metastases are a frequent event in patients with solid tumors. Although great advances have been made in the treatment of these patients, the identification of novel, accurate indicators of bone response would greatly facilitate the clinical management of the disease. The receptor activator of nuclear factor‑κB (RANK)/RANK ligand (RANKL)/osteoprotegerin (OPG) signaling pathway is significantly involved in bone metastasis formation. The main aim of the present study was to evaluate the role of circulating RANK, RANKL and OPG levels in predicting bone response. Marker accuracy was also compared with that of the conventional tumor marker N‑terminal telopeptide of type I collagen (NTX). A prospective study was performed on 49 patients with bone metastases from breast, lung and prostate cancer, who were undergoing treatment with zoledronic acid. Patients were monitored for 1 year with blood tests, clinical evaluation and instrumental exams according to the response evaluation criteria of the University of Texas M. D. Anderson Cancer Center (Houston, TX, USA) and the Positron Emission Tomography Response Criteria in Solid Tumors. Circulating RANK/RANKL/OPG transcripts and NTX levels were evaluated by reverse transcription-quantitative polymerase chain reaction and immune enzymatic assay, respectively. The baseline RANKL levels differed significantly between responders and non‑responders, whereas no differences in NTX levels were observed between the two groups. Receiver operating characteristic curve evaluation for all markers revealed that RANKL was the most accurate marker, with an area under the curve of 0.74 (95% confidence interval, 0.54‑0.93). In addition, RANKL, which is the target of the novel monoclonal antibody denosumab, was the most accurate predictor of bone response in the present series of patients with bone metastases. Thus, the use of RANKL as a marker could potentially improve clinical practice, as current bone response evaluation is still somewhat problematic.Keywords
This publication has 28 references indexed in Scilit:
- What can we learn from the ZOOM trial? – Authors' replyThe Lancet Oncology, 2013
- Prospective Study of Urinary and Serum Cross-Linked N-Telopeptide of Type I Collagen (NTx) for Diagnosis of Bone Metastasis in Patients With Lung CancerClinical Lung Cancer, 2013
- A new emergency in oncology: Bone metastases in breast cancer patients (Review)Oncology Letters, 2013
- RANK/RANK-L/OPG in Patients with Bone Metastases Treated with Anticancer Agents and Zoledronic Acid: A Prospective StudyInternational Journal of Molecular Sciences, 2013
- Role of RANK, RANKL, OPG, and CXCR4 Tissue Markers in Predicting Bone Metastases in Breast Cancer PatientsClinical Breast Cancer, 2011
- Cancer to bone: a fatal attractionNature Reviews Cancer, 2011
- Bone markers and their prognostic value in metastatic bone disease: Clinical evidence and future directionsCancer Treatment Reviews, 2008
- Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acidCancer, 2008
- Predictive Value of Bone Resorption and Formation Markers in Cancer Patients With Bone Metastases Receiving the Bisphosphonate Zoledronic AcidJournal of Clinical Oncology, 2005
- Bone Turnover Markers as Predictors of Skeletal Complications in Prostate Cancer, Lung Cancer, and Other Solid TumorsJNCI: Journal of the National Cancer Institute, 2005